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The association of the clinical and laboratory indications of primary hyper- 
parathyroidism  with  malignant  non-parathyroid  tumors  not  metastatic  to 
bone has been reported in at least 18 cases (1, 2). The rapid disappearance of 
hypercalcemia following removal of  the  tumor  and  the  reappearance  of an 
elevated serum calcium on recurrence of the tumor have been considered in- 
direct or. circumstantial evidence that the neoplasms themselves may produce 
a parathyroid hormone-like substance (1, 2). Demonstration of ectopic ACTH 
in non-pituitary neoplasms associated with Cushing's syndrome, and the find- 
ing of other hormone-like substances in non-endocrine tumors (3, 4) have es- 
tablished the concept that a variety of neoplastic tissues may display endocrine 
activity. 
Previous attempts to use biological assay methods to identify directly a parathyroid 
hormone-like  substance  in malignant tumors were unsuccessful probably because of 
the insensitivity of the methods used.  The availability of an antiserum to bovine 
parathyroid hormone (5), and the finding of immunochemical cross-reactivity between 
extracts of bovine and human parathyroid glands with anti-bovine antibody (6) have 
enabled us to detect, by quantitative complement (C  ~) fixation, an antigen reacting 
with antiparathyroid hormone in 6 tumors obtained from patients with the hyper- 
calcemic  syndrome.  This  C  t fixation assay method is several hundred times more 
delicate than the biological assay methods previously used to assay such neoplasms. 
The immunochemical evidence that the tumor antigen is either human para- 
thyroid hormone or a very closely related molecule is presented in this report. 
* Contribution No. 266 of the Graduate Department of Biochemistry,  Brandeis  University, 
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In addition  to  offering the  first direct evidence for production  of parathyroid 
hormone by non-parathyroid  neoplasms,  these data also demonstrate  serologic 
differences between human  and  bovine parathyroid  hormones. 
Materials and Methods 
Parathyroid Hormone Preparations.--Two  highly purified parathyroid  hormone prepara- 
tions were used. They were prepared from phenol extracts of acetone powder of bovine para- 
thyroid glands  (Wilson  Labs., Chicago), fractionated by the method of Aurbach  (7)  to the 
stage of the trichloroacetic acid precipitate. 
Preparation A, used as the immunizing antigen, was further purified by two successive  gel 
filtrations through  columns  of sephadex  G-50,  following the procedure  of Rasmussen  and 
Craig (8). Amino acid analyses  1 by the method of Spackman et al. (9) were in good agreement 
with those previously reported by Rasmussen and Craig (8) for highly purified bovine para- 
thyroid hormone. The specific activity of preparation A in the bioassay method of Munson 
(10) was as high as or higher than any previously reported, 40,000  x  1.21 units/mg nitrogen. 2 
Protein nitrogen was estimated by the method of Lowry et al. (11). 
Preparation B was purified by an independent method, countercurrent distribution, using 
the salt system of Aurbach (7). 
Antiserum.--One mg of parathyroid hormone preparation A, dissolved in 1.0 ml of 0.005 
N acetic acid and emulsified with 1.0 ml of complete Freund's adjuvant was administered to a 
single albino rabbit by simultaneous toe-pad and intramuscular injections. Beginning 3 weeks 
after the initial immunization, an intravenous injection of 150/zg of the same antigen was given 
daily for 5 days. The rabbit was bled I week after the last intravenous injection, and the serum 
recovered was stored at --20°C without preservative. 
Quantitative Complement (C') Fixation.--Quantitative  C' fixation was performed  as pre- 
viously described (5), In the present experiments the diluent was isotonic NaCl-tris-(hydroxy- 
methyl)-aminomethane buffer,  pH 7.3, containing 5 X  10  -4 ~  MgCl2 and 1.5 X  10-4 M CaCI2 
but no added protein. The dilution of antibody used is given in the description of each specific 
experiment. C r fixation inhibition was performed as described by Wasserman and Levine (12). 
Before addition to the final reaction mixture the diluted antigens were subjected to sonic oscil- 
lation for 3 minutes (5). 
Immunochemical ttomogeneity.--On  vertical starch gel electrophoresis of the immunizing 
antigen (preparation A) a dense, narrow protein band appeared with the characteristic mobility 
of parathyroid  hormone as shown previously by immunological and biological assays of gel 
eluates (5). A second  very weak band corresponded to material that was biologically and im- 
munologically inactive. Hormone preparation  B, on electrophoresis in the same starch gel 
system, migrated as a  single,  dense,  narrow band with the same mobility as the major bio- 
logically and immunologically active band obtained with the gel filtration product  (prepara- 
tion A)  (5).  Identical C r fixation curves were obtained with the two preparations.  Double 
diffusion in agar, for 72 hours at 4 ° or 20°C, of the immunizing preparation, crude parathyroid 
gland  extracts  (300  units/rag  N), and  undiluted  or even 4  times concentrated  antiserum, 
gave only a  single  band of precipitation (5).  Complement fixation in far antigen excess gave 
no evidence of a  second  immune system  (5).  The good agreement between immunoassays 
(using this antiserum) and bioassays of parathyroid hormone preparations of widely varying 
1 The empirical formula  was:  lysT, hiss,  arg4,  aspT, thrl,  sets,  glug, pro3, gly 4, ala7, vals, 
met1, ileum, leus, tyrl, phe~, try1.  We are greatly indebted to Dr. Helen Van Vunakis and Mr. 
Fred Castillo, Graduate Department of Biochemistry, Brandeis University, for these analyses. 
The factor following the symbol  +x, when multiplied  by and  divided  into  the potency 
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potencies  (5)  is  further  evidence  of  the  homogeneity  and  specificity  of  the  antiserum. 
The use of rabbit antiserum against parathyroid hormone to precipitate the highly purified 
hormone from solution and the recovery of the biological activity from the immune precipitate, 
have been reported previously (13). 
Biological Assay.--In this paper the term biological activity refers to activity in the assay 
method of Munson (10), which is based on the maintenance of the serum calcium level in 
acutely parathyroidectomized rats. The results were evaluated by standard statistical pro- 
cedures for parallel-line assays according to Finney (14). 
TABLE  I 
Clinical Data 
Wulnor 
Case 
No.  Metas- 
Type  tasis to 
1  Renal cell 
2  Renal cell*  Lung 
3  Pancreas  Liver 
4  Renal cell 
5  Lung 
6  Colon§  Liver 
Parathyroid 
glands 
Not exam- 
ined 
Atrophic 
Normal 
Normal 
Not exam- 
ined 
Normal 
Serum 
Inor- 
Calcium  ganic 
phos- 
phate 
mg/lO0 ml 
14.0-15.4  2.9-4.5 
11.4-18.6  1.8-3.6 
i 
l 
17.0  _  i 
>,4o  730i 
9.6-15.4  1  0 
I 
15.2-18.6  2.0  i 
I 
Alkaline 
phosphatase 
units 
4.1-6.2 
(Bodansky) 
O.9-3.7 
(Bessey- 
Lowry) 
1.7-3.5 
(Bessey- 
Lowry) 
16.5 
(Bodansky) 
Other 
TRP:~ =  68 
per cent 
TRP  =  73 
per cent 
* For a  detailed description of the clinical aspects of this case see Goldberg eg al. (2). 
Tubular reabsorption of phosphate. 
§ See Case Records of the Massachusetts General Hospital: Case 63-1963, New England J. 
Med.,  1963, 269, 801. 
Tissue Extracts.-- 
(a) Urea extracts of human and bovine parathyroid tissue:  Normal human parathyroid glands 
obtained at autopsy or human parathyroid adenomas were homogenized with acetone (500 
ml/gm) and then stirred for 24 hours at 4°C. The powder was obtained following filtration and 
washing with fresh acetone.  Either  commercial acetone powders  or  freshly ground whole 
parathyroid glands were the source of bovine material. The powders or ground tissue were 
stirred with aqueous 8 ~x urea (20 ml/gm) for 2 to 3 hours at 25°C. The insoluble residue was 
removed by centrifugafion at 3000 g for 15 minutes at 4°C and the clear supematant was 
stored at 2-4°C. Storage in the frozen state was avoided because an insoluble precipitate was 
found after thawing and the immunological activity had decreased. 
(b)  Dilute hydrochloric acid extracts of bodne and human parathyroid tissue: Normal bovine 
and human parathyroid glands and human parathyroid adenomas, freshly ground or acetone 
powders, were stirred with 0.1 s  HC1 (10 ml/gm) for 15 minutes in a water bath at 1000C. 
Lipid was removed from the extracts by filtration through glass wool and the insoluble ma- 470  PARATHYROID  HORMONE  IN  NON-PARATHYROID  NEOPLASMS 
terial, separated by centrifugation at 3000 g for 15 minutes at 4°C, was discarded. Some of the 
preparations were adjusted to pH 11.0 with 5 N NaOH and then back titrated to pH 8.0 with 
1 N HC1. Any insoluble material was again removed by centrifugation. This simple purifica- 
tion step, which did not alter the serological activity, facilitated testing for C' fixation at 
relatively low dilutions. These extracts were stored at  -20°C. 
(c)  Phenol  extracts of human  parathyroid  tissue:  Acetone powders of human parathyroid 
tissue (prepared as described above) were stirred with 88 per cent phenol (10 ml/gm) con- 
taining 0.05 ~r 2-mercaptoethanol. The mixture was then carried through the next step in the 
Aurbaeh method for preparation of bovine parathyroid hormone (7), the formation of the 
ether precipitate; the precipitate was then taken up in 0.01 N HCI. Any material not in solu- 
tion after 3 hours' stirring at 4°C was removed by centrifugation and the clear supernate was 
stored at --20°C. 
All extracts of both human and bovine parathyroid glands tested in this study were bio- 
logically active. 
(d)  Extracts  of human neoplasms and control tissues: Tumor and control (non-tumor) tis- 
sues were obtained at surgery or autopsy from 6 hypercalcemic patients who had no evidence 
(clinical, radiological, or pathological) of osseous metastases. Table I  shows the pathological 
and clinical laboratory data from these patients. In addition, 7 human tumors,--carcinomas 
of pancreas (two), lung, colon (two), breast, and a  neuroblastoma,---obtained from patients 
without hypercalcemia were obtained and treated in an identical manner. The specimens were 
stored at  --20°C until extraction. Following partial defatting and dehydration with acetone 
(100 ml/gm,  24 hours, 4°C)  3  types of extracts were prepared from the resulting powders. 
Each specimen was extracted with aqueous 8 ~¢ urea exactly as described for parathyroid tis- 
sue. Phenol and dilute HC1 extracts of certain specimens were likewise prepared in a manner 
identical with that described for parathyroid glands. Urea extracts were stored at 4°C until 
assay (less than 48 hours later). The phenol and HC1 preparations were kept frozen until use. 
RESULTS 
Serologic Activity of Bovine Parathyroid Hormone Obtained by Three Different 
Extraction Procedures.--Figs.  1 A  and 1 B  show, respectively, the C I fixation 
obtained with the highly purified phenol-extracted bovine parathyroid hormone 
and with an 8 ~t urea extract of bovine parathyroid tissue at an antibody dilu- 
tion of 1/1500. The HC1 extract lacked the capacity to fix C I with this dilution 
of antiserum, but it did react with the antiparathyroid hormone as measured 
by inhibition of C' fixation by the homologous (phenol-extracted) parathyroid 
hormone-antiparathyroid hormone (Fig.  1 C). 
Serologic Activity  of Human Parathyroid Gland  Extracts  Obtained by  Three 
Different  Extraction  Procedures.--Direct  C' fixation between the urea extract 
of human parathyroid glands and antibovine hormone was seen at an antibody 
dilution of 1/100 (Fig. 2 A). No C ~ fixation was observed with the antiserum 
dilution used to detect homologous antigen  (1/1500); however, this  urea ex- 
tract did inhibit the homologous C' fixation at an antiserum dilution of 1/1500. 
As in the bovine system, the HC1 extract of human glands did not fix C ~ di- 
rectly even at an antibody dilution of 1/100  (Fig.  2 A).  It was,  however, a 
potent inhibitor of the bovine system  (Fig.  2 B).  Phenol extracts of human 
parathyroid tissue also did not fix C p directly, but did show  100 per cent in- ~I°° 
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hibition (at an inhibitor concentration of 10/~g N) of the homologous system 
even at an antibody dilution of 1/400. It is possible that the lack of direct C' 
fixation with phenol extracts of human glands, as well as the need for a higher 
concentration of antibody for direct reaction with urea-extracted human anti- 
gen than for bovine hormone, reflect alterations in the human hormone during 
extraction. However, because of the relatively mild conditions of these extrac- 
tion methods applied similarly to both species the more reasonable explanation 
is that the antigenic sites on the human molecule, although similar to, are not 
identical with those sites on the bovine hormone, thus giving rise to true im- 
munochemical  cross-reactivity  frequently  observed  between  organ-specific 
proteins of different species  (15).  Unpublished data obtained in our laboratory 
with phenol and HC1  extracts of rat parathyroid glands also show immuno- 
chemical cross-reactivity, but not identity, with bovine hormone. Neither type 
of rat extract fixed C' directly with anti-bovine antibody, although again each 
of them was a potent inhibitor of the homologous system. 
Serologic Activity of Human Tissue  Extracts.--Fig. 3 A  shows the direct C' 
fixation obtained with urea extracts of the tumors  obtained from six hyper- 
calcemic patients.  The antibody dilution was 1/200. Also shown is the lack of 
direct C' fixation with the urea extract from case 1 at an antiserum dilution of 
1/1000 (Fig. 3 A). The finding that the human parathyroid gland extract (urea) 
fixed C' at an antibody dilution of 1/100 while the  tumor extracts reacted at 
1/200,  does not necessarily  demonstrate lack of identity between these two 
antigens. It is more likely that this difference reflects the small concentration of 
antigen in the parathyroid tissue examined,  placing this reaction far into the 
zone of antibody excess. The shape and rising nature of the  C' fixation curve 
for the human gland extract (Fig. 2 A) are fully compatible with this reasoning. 
At high concentrations the anticomplementary properties of the tumor extracts 
prevented attainment of peak fixation (cases 3 to 6) and description of the zone 
of antigen excess inhibition (all cases). In the three cases  (Nos.  2,  3,  and 6) 
in which metastatic tumor was available for assay, urea extracts reacted di- 
rectly with antibody (Fig. 3 A  and Table I) while extracts of the tissue im- 
mediately adjacent to the metastasis gave no C' fixation. Likewise, urea extracts 
of uninvolved organs from the same cancer patients gave uniformly negative 
reactions. The antigen was also not detected in any of the urea extracts of the 7 
neoplasms not associated with hypercalcemia. 
As seen in Fig. 3 B, urea extracts of tumor also inhibited the homologous re- 
action even at an antibody dilution of 1/1000.  Control extracts were ineffective 
as inhibitors. Both HC1 and phenol extracts of tumors, like these two types of 
extracts of human parathyroid glands, failed to fix C t directly at an antiserum 
dilution of 1/200, but they did retain the capacity to inhibit the bovine hor- 
mone-antihormone system. Fig. 4 shows this inhibition by an HC1 extract at 
two antibody dilutions. °  "~.,,.., 
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Tests for non-specific inhibition  of C' fixation by all types of tumor and para- 
thyroid  gland  extracts  with  three  other  independent immune systems  (egg 
albumen, pepsinogen, and hemoglobin) were entirely negative. 
Absorption of Antiparatkyroid Hormone with Tumor Antigen.- 
In three experiments rabbit antiserum was absorbed with tumor extracts and tested for 
antibody titer against the homologous bovine antigen. In these experiments urea tumor ex- 
~  4o 
,7  "o~  2o~ 
I  =  i 
o  200  400  6bo  BbO 
~lO  INHIBITOR  N  ADDED 
FIo. 4.  Complement fixation inhibition  by 0.1 N HC1 extract of tumor (No. 4), antiserum 
diluted 1/300 and 1/1000. There was no direct C' fixation with this HCI extract at either dilu- 
tion of antiserum. Phenol extracts of the tumors, like the HC1 extract shown, did not fix C' 
directly, but they were potent (up to 100 per cent) inhibitors of the homologous  bovine system 
at an antiserum dilution  of 1/1500. 
tracts were dialyzed in 8/32 V'mking  tubing twice against 400 volumes of 0.15 M  NaC1 at 4°C 
for 30 minutes each. An absorption mixture was then prepared in buffer which contained anti- 
serum at a final dilution of 1/20, and an amount of tumor antigen calculated from the C' 
fixation data (Fig. 3 A) to approximate the equivalence zone. Mixtures containing control 
tumors  (not  giving direct  C' fixation) plus  antiserum,  and control antiserum  alone were 
handled identically. Following storage at 2°C for 2, 4, or 6 days, the reaction mixtures were 
centrifuged at 2000 ~,~ at 4°C for 60 minutes and the superuatant solutions were then diluted 
appropriately immediately before assay. 
Figs. 5 A  to 5 C  show  the  results of  these absorption experiments. A  con- 
sistent decrease in titer  (40, 49,  and 40 per cent at peak  C' fixation) toward 
the homologous test antigen was observed in each experiment (Figs. 5  A  to 476  PARATHYROID  HORMONE  IN  NON-PARATHYROID  NEOPLASMS 
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5 C). No loss in titer was observed in absorption with control tumors. No de- 
tectable  antibody toward  the  tumor  antigen remained  in  the  supernatant 
solution after absorption at an antiserum dilution of 1/200. 
To provide  evidence that the antibody absorption experiments  signify the 
removal of a cross-reacting rather than a contaminating antibody, it was neces- 
sary to show that C' fixation, at a dilution of antiserum where a major system 
was being measured,  was not quantitatively influenced by the presence of a 
minor independent antigen-antibody system not fixing C' directly at that anti- 
body  concentration. This  hypothesis was  tested  by preparing  an  artificial 
heterogeneous mixture of antibodies in which the proportion of minor to major 
antibodies was 1 to 5 as judged by direct C' fixation. This ratio (1 to 5, or 20 
per cent) was specifically chosen to exceed slightly the proportion of a hypo- 
thetical contaminating antibody in the parathyroid hormone system. If it were 
argued that the antibody reacting with the human tumor antigen at a dilution 
of 1/200 was a minor antibody, and that the antibody reacting with purified 
parathyroid hormone at a dilution of 1/1500 was a major, but independent, 
antibody, the ratio of these two systems would be 1 to 7.5 (13 per cent). Figs. 
6 A and 6 B indicate, respectively, the homologous C' fixation curves obtained 
with swine gastric pepsinogen  and its antibody at a  dilution of 1/4000 and 
chicken hemoglobin and its antibody at a dilution of 1/2000. No C' fixation 
with hemoglobin was seen at an antibody dilution of 1/10,000 (Fig. 6 C). In 
the experiment shown in Fig. 6 D, the antigen was an artificial mixture of both 
pepsinogen and hemoglobin and the antibody was also a mixture of both anti- 
pepsinogen  (1/4000)  and  antihemoglobin  (1/10,000).  The  C'  fixation  curve 
obtained (Fig. 6 D) was identical with the pepsinogen curve obtained in the 
absence of the second contaminating system (Fig. 6 A). Thus, the consistent 
decrease  in C' fixation  in the parathyroid hormone system after absorption 
must represent removal of cross-reacting antibody. 
Biological Assay.--The immunochemically  active urea extracts of nonpara- 
thyroid tumors were tested in a preliminary manner for biological activity by 
the Munson method (10). As shown in Table II, there was a small but statis- 
tically significant effect consistent with the presence of parathyroid hormone. 
In order to increase the dose per rat in the bioassay the activity in the urea 
extracts  was  concentrated by  precipitation  with  trichloroacetic  acid  (final 
concentration, 6 per cent). The precipitate was washed with ether and dissolved 
in a small volume of 0.1 N I-IC1. 
Estimation of Parathyroid Hormone in Tumors.--Although  the tumor antigen 
is related to the homologous bovine antigen it is not identical with it. Conse- 
quently, estimates of the antigen content of the  tumors,  using  anti-bovine 
parathyroid hormone, can be expressed only in relative,  not absolute,  terms. 
The correction factor for conversion of these relative values to absolute values 
cannot be determined matil the human tumor hormone is available in a homo- 478  PARATHYROID HORMONE  IN  NON-PARATHYROID NEOPLASMS 
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geneous state. However, quantitative immunochemical studies of the antigenic 
relatedness of ovalbumin (15), and of hemoglobins, lactic dehydrogenases (H4 
and  M4),  triosphosphate  dehydrogenases,  and  glutamic dehydrogenases  (16) 
have shown, even with cross-reactions detected at a 1/1000 dilution of antiserum 
TABLE II 
Biological Response of Acutely Parathyroidectomized Rats to Tumor Extracts 
Preparation  No.  Mean plasma calcium 
mg/lO0 ~nl 4- SE 
Control ........................................  5  6.38  4-  0.41 
15 units, u.s.P parathyroid hormone ...............  5  7.80  4- 0.41" 
Tumor extracts  (Nos. 1, 2 and 4) .................  14  7.54  4- 0.24* 
* P  <  0.05, greater  than control. Control solution contained reagents without the tissue 
proteins. 
TABLE III 
Immunoassay Data  from 6 Cases of Hyperparathyroidism Associated with Parathyroid 
Hormone-Producing Neoplasms 
Ca~ No. 
4 
5 
6 
Tumors without hypercalcemia:~ 
Amount of parathyroid hormone measured by immunoassay 
Tumor tissue 
Primary 
~&/gm 
13  (1.1)* 
10 (1.2) 
6  (1.1) 
11  (1.1) 
2  (1.2) 
6  (1.1) 
None detected 
Metastatic 
~g/gm 
39  (1.2) 
0.9  (1.3) 
1.1  (1.2) 
Non-tumor tissue in 
which no hormone 
was detected 
Kidney 
Lung 
Liver 
Kidney 
Adrenal 
Liver 
* The number in parenthesis,  when multiplied by and divided  into the estimate of hor- 
mone content,  gives the limits of the standard error. 
Carcinomas of pancreas  (two), lung, colon (two), breast, neuroblastoma. 
where the homologous C' fixation is obtained at  1/20,000,  that C' fixation at 
their  respective  equivalence  zones  was  obtained  with  similar  quantities  of 
antigen. As these data indicate that the error involved in estimation of a cross- 
reacting antigen in the zones of antibody excess and equivalence may be small, 
we considered it meaningful to estimate  the hormone content of these hyper- 
calcemic tumors by immunoassay (5). 480  PARATHYROID  HORMONE  IN  NON-PARATHYROID  NEOPLASMS 
The immunoassay values for the human tumor tissues are given in Table III 
in  terms of #g of the highly purified bovine reference standard,  3.5  .._x 1.18 
units/#g, assuming an equal efficiency  of extraction for both parathyroid glands 
and  tumors.  The  estimates  of  biological  activity in  the  extracts  examined 
(Table II) were consistent with the immunoassays. 
DISCUSSION 
The conclusion reached in this paper  that a  constituent of certain human 
tumors associated with hypercalcemia is closely similar to, probably identical 
with, parathyroid hormone is based largely on immunological evidence. The 
validity of this evidence depends on the specificity and homogeneity of the 
antiparathyroid hormone used. 
With respect to the specificity of the antibody, it had been shown previously 
that the solution of a washed immune precipitate formed with purified para- 
thyroid hormone contained the biological activity characteristic of the hormone 
(13). In addition, immunoassays of numerous parathyroid gland extracts cover- 
ing a wide range of specific activities agreed well with biological assays of the 
same extracts (5). 
The homogeneity of the antiserum was supported first by double diffusion 
experiments in which crude parathyroid gland extracts as well as the purified 
hormone gave only one band of precipitation even with concentrated antiserum 
(5). Secondly, both crude and purified parathyroid hormone preparations gave 
only a single C' fixation curve with the antiserum over a wide range of antigen 
concentrations, even in far antigen excess. If a contaminating antigen-antibody 
system were present,  a  second  C' fixation curve would probably have  been 
observed  (17).  Thirdly,  the  excellent correlation  of immunoassays of  para- 
thyroid hormone over a wide range of specific activities with biological assays 
decreases the likelihood of a  contaminating antigen-antibody system. Finally, 
bovine parathyroid hormone purified in our laboratory by two different meth- 
ods, and a  sample prepared in another laboratory by Dr.  Gerald D. Aurbach 
(13), all gave the same C' fixation curves. 
From the foregoing argument we assume that the antigen found in certain 
human tumors and in human parathyroid glands is human parathyroid hor- 
mone.  The increased anti-bovine parathyroid hormone required  to visualize 
the human antigen by C' fixation (1/100 or 1/200 compared with 1/1500 for 
the bovine hormone)  is probably a  function of conformational dissimilarity 
between the human and bovine hormones. Evidence for antigenic relatedness, 
by these same criteria, has been shown previously in 5 different antigen-anti- 
body systems (16). 
However, the possibility could be considered that the 7 to 13 per cent cross- 
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tamination too small in quantity to detect by the procedures  used to test for 
heterogeneity of the antiserum. If this were true, absorption of the antiserum 
with the contaminating antigen should not decrease the titer to the homologous 
purified bovine parathyroid hormone as measured by our C' fixation procedure. 
To  assess this  possibility,  we prepared  a  heterogeneous  immune system in 
which  a  minor antibody was present as a  20 per cent contaminant. The C' 
fixation of the major antigen-antibody system, at high antiserum dilution, was 
unaffected by the contaminating antigen-antibody system (Figs. 6 A to 6 D). 
However,  absorption of the antiparathyroid hormone with tumor antigen de- 
creased the antibody titer to the purified bovine parathyroid hormone (Figs. 
5 A to 5 C). This consistent 40 to 50 per cent decrease in C' fixation by the 
purified  hormone with  the  antiparathyroid hormone after  absorption  with 
tumor extracts would be expected to be only of this magnitude since the cross- 
reaction is only 7 to 13 per cent (16). 
The demonstration, with the artificially prepared heterogeneous  antiserum, 
that the C' fixation of a major system at a high dilution of antiserum is un- 
affected by the presence of a 20 per cent contaminating system, reinforces the 
conclusion that the 70 to 100 per cent inhibition by HC1 and phenol extracts of 
human parathyroid glands and tumors represents inhibition of antiparathyroid 
hormone antibody. In spite of the demonstrated homogeneity, if it were argued 
that two antibody systems were being measured at this high dilution (1/1000 
to 1/1500)  of antiserum, then inhibition could be only partial (less than 100 
per  cent), unless,  of course,  the tumor extracts contained both parathyroid 
hormone  and  a  contaminating  inhibitor.  Furthermore,  unpublished  data 
from our laboratory show that inhibition of C' fixation is only partial when 
impure antisera are reacted with pure synthetic haptens (18). The reason for 
the lack of C' fixing activity in the presence of inhibiting capacity is unknown 
at this time. The most likely explanation is that the phenol and HC1 extraction 
procedures alter the conformation and molecular weight of the antigen (19, 20). 
Studies  with the pepsinogen-pepsin  immune system (21) and of the DNA 
immune system (22) have shown that the antigen molecule can be changed from 
an antigen that fixes C' directly with antibody to one that will no longer fix C' 
directly but  still will react with antibody as evidenced  by inhibition of C' 
fixation. With respect  to the pepsinogen-pepsin immune system, these altera- 
tions in the antigen are conformational changes (23), while in the DNA system 
they are a function of molecular weight (22). 
Further support for the conclusion that the tumor antigen represents  para- 
thyroid hormone follows from the lack of detectable antigen in control tissues 
from the same patients whose tumors contained antigen and in tumors of the 
same organs from patients without hypercalcemia  (Table III). One additional 
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cause the patient's serum was not analyzed for calcium. Further study will be 
necessary to determine to what  extent this  antigen is characteristic of renal 
cell carcinomas generally. 
Production of parathyroid  hormone by  the  tumor  tissue  rather  than  ac- 
cumulation of the hormone in the tumor from another source is supported by 
the findings in two of the present cases. Serum calcium in case 1 fell from 15.4 
to  8.0 rag/100 ml  following removal of the  tumor,  while  tumor recurrence, 
weeks later, was accompanied by return of hypercalcemia. In case 2, careful 
anatomic examination of the patient's own parathyroid apparatus  (2) showed 
abnormalities indicative of decreased function. 
Further confirmation of the results reported here should be forthcoming from 
measurements  of increased hormone concentration in  the  serum  of patients 
with this hypercalcemic syndrome. We have examined the serum from only one 
patient,  No.  3,  by C' fixation.  A  small but definite amount of antigen was 
measured (at an antibody dilution of 1/200), indicating a circulating hormone 
level in excess of 10 m#g/ml. To date we have not detected hormone in the 
serum of any normal person by this method, which is as expected in view of the 
preliminary data obtained by the radioimmunoassay method of Berson et al. 
(24), showing not more than 0.1  to  1.0 m/zg/ml in normal human plasma,  a 
concentration too low to be detected by the C t fixation assay method as it is 
presently conducted. 
Because of the large mass of the hypercalcemic neoplasms and the relatively 
high concentration of hormone in them, it may be possible to use them as source 
material for the isolation and further characterization of human parathyroid 
hormone. 
S~RY 
1.  Immunochemical  cross-reactivity,  but  not  identity,  has  been  demon- 
strated between bovine parathyroid hormone and  an antigen in  biologically 
active extracts of human parathyroid tissue by quantitative C t fixation and C' 
fixation inhibition. 
2.  An antigen that fixes C t with rabbit antibody to bovine parathyroid hor- 
mone has been found in urea extracts of six human non-parathyroid neoplasms 
associated  with  a  hypercalcemic  syndrome  mimicking  primary  hyperpara- 
thyroidism.  Comparable  extracts  of  control  tissues  and  other  tumors  were 
serologically negative. 
3.  It is concluded that the tumor antigen is parathyroid hormone or a very 
closely related protein, and that  its production by these neoplasms was  the 
cause of the hypercalcemic syndrome in these six patients. 
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